Genotoxicity and Subchronic Toxicological Study of a Novel Ginsenoside Derivative 25-OCH-PPD in Beagle Dogs

Overview

Journal J Ginseng Res

Date 2019 Nov 9

PMID 31700258

Citations 4

Authors

Wei Li

Xiangrong Zhang

Meng Ding

Yanfei Xin

Yaoxian Xuan

Yuqing Zhao

Affiliations

Soon will be listed here.

Abstract

Background: Ginsenosides have been widely used clinically for many years and were regarded as very safe. However, a few researches on the toxicities of these kinds of agents showed that some ginsenosides may have side-effect on the rats or dogs. So it is extremely necessary to further clarify the potential toxicity of ginsenosides. This study was carried out to investigate long-term toxicity and genotoxicity of 25-methoxydammarane-3, 12, 20-triol (25-OCH-PPD), a new derivative of ginsenoside, in beagle dogs.

Methods: Twenty-four beagle dogs were divided randomly into four treatment groups and repeatedly orally administered with 25-OCH-PPD capsule at 60, 120, and 240 mg/kg/day for 91 consecutive days. Ames, micronucleus, and chromosomal aberration tests were established to analyze the possible genotoxicity of 25-OCH-PPD.

Results: There was no 25-OCH-PPD-induced systemic toxicity in beagle dogs at any doses. The level of 25-OCH-PPD at which no adverse effects were observed was found to be 240 mg/kg/day. The result of Ames test showed that there was no significant increase in the number of revertant colonies of 25-OCH-PPD administrated groups compared to the vehicle control group. There were also no significant differences between 25-OCH-PPD administrated groups at all dose levels and negative group in the micronucleus test and chromosomal aberration assay.

Conclusion: The highest dose level of 25-OCH-PPD at which no adverse effects were observed was found to be 240 mg/kg per day, and it is not a genotoxic agent either in somatic cells or germs cells. 25-OCH-PPD is an extremely safe candidate compound for antitumor treatment.

Citing Articles

Bioconversion, Pharmacokinetics, and Therapeutic Mechanisms of Ginsenoside Compound K and Its Analogues for Treating Metabolic Diseases.

Morshed M, Akter R, Karim M, Iqbal S, Kang S, Yang D Curr Issues Mol Biol. 2024; 46(3):2320-2342.

PMID: 38534764 PMC: 10968794. DOI: 10.3390/cimb46030148.

Rare ginsenosides: A unique perspective of ginseng research.

Fan W, Fan L, Wang Z, Mei Y, Liu L, Li L J Adv Res. 2024; 66:303-328.

PMID: 38195040 PMC: 11674801. DOI: 10.1016/j.jare.2024.01.003.

Microorganisms for Ginsenosides Biosynthesis: Recent Progress, Challenges, and Perspectives.

Chu L, Huy N, Tung N Molecules. 2023; 28(3).

PMID: 36771109 PMC: 9921939. DOI: 10.3390/molecules28031437.

A narrative review of the pharmacology of ginsenoside compound K.

Liu T, Zhu L, Wang L Ann Transl Med. 2022; 10(4):234.

PMID: 35280413 PMC: 8908159. DOI: 10.21037/atm-22-501.

References

Liu J, Lu D, Nicholson R, Li P, Wang F . Toxicity of a novel anti-tumor agent 20(S)-ginsenoside Rg3: a 26-week intramuscular repeated administration study in Beagle dogs. Food Chem Toxicol. 2011; 49(8):1718-27. DOI: 10.1016/j.fct.2011.04.017. View

Lu D, Liu J, Zhao W, Li P . Chronic toxicity of ginsenoside Re on Sprague-Dawley rats. J Ethnopharmacol. 2012; 144(3):656-63. DOI: 10.1016/j.jep.2012.10.007. View

Chan R, Chen W, Dong A, Guo D, Wong M . Estrogen-like activity of ginsenoside Rg1 derived from Panax notoginseng. J Clin Endocrinol Metab. 2002; 87(8):3691-5. DOI: 10.1210/jcem.87.8.8717. View

Wang W, Rayburn E, Hang J, Zhao Y, Wang H, Zhang R . Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. Lung Cancer. 2009; 65(3):306-11. PMC: 2748063. DOI: 10.1016/j.lungcan.2008.11.016. View

Park S, Lim K, Noh J, Jeong E, Kim Y, Han B . Subacute oral toxicity study of korean red ginseng extract in sprague-dawley rats. Toxicol Res. 2014; 29(4):285-92. PMC: 3936181. DOI: 10.5487/TR.2013.29.4.285. View

Wang W, Zhao Y, Rayburn E, Hill D, Wang H, Zhang R . In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemother Pharmacol. 2006; 59(5):589-601. DOI: 10.1007/s00280-006-0300-z. View

Zhang X, Zhang J, Li W, Liu L, Sun B, Guo Z . In vitro metabolism of 20(R)-25-methoxyl-dammarane-3, 12, 20-triol from Panax notoginseng in human, monkey, dog, rat, and mouse liver microsomes. PLoS One. 2014; 9(4):e94962. PMC: 3988085. DOI: 10.1371/journal.pone.0094962. View

Wang C, Xie J, Zhang B, Ni M, Fishbein A, Aung H . Chemopreventive effects of Panax notoginseng and its major constituents on SW480 human colorectal cancer cells. Int J Oncol. 2007; 31(5):1149-56. PMC: 2676859. View

Yang Z, Sun H, Ye Y . Ginsenoside Rd from Panax notoginseng is cytotoxic towards HeLa cancer cells and induces apoptosis. Chem Biodivers. 2006; 3(2):187-97. DOI: 10.1002/cbdv.200690022. View

10.

Schmid W . The micronucleus test. Mutat Res. 1975; 31(1):9-15. DOI: 10.1016/0165-1161(75)90058-8. View

11.

Cui C, Kim S, Im W . Characterization of the ginsenoside-transforming recombinant β-glucosidase from Actinosynnema mirum and bioconversion of major ginsenosides into minor ginsenosides. Appl Microbiol Biotechnol. 2012; 97(2):649-59. DOI: 10.1007/s00253-012-4324-5. View

12.

Li D, Cao J, Bi X, Xia X, Li W, Zhao Y . New dammarane-type triterpenoids from the leaves of Panax notoginseng and their protein tyrosine phosphatase 1B inhibitory activity. J Ginseng Res. 2014; 38(1):28-33. PMC: 3915329. DOI: 10.1016/j.jgr.2013.11.013. View

13.

Shishtar E, Sievenpiper J, Djedovic V, Cozma A, Ha V, Jayalath V . The effect of ginseng (the genus panax) on glycemic control: a systematic review and meta-analysis of randomized controlled clinical trials. PLoS One. 2014; 9(9):e107391. PMC: 4180277. DOI: 10.1371/journal.pone.0107391. View

14.

Wang W, Zhang X, Qin J, Voruganti S, Nag S, Wang M . Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2. PLoS One. 2012; 7(7):e41586. PMC: 3402429. DOI: 10.1371/journal.pone.0041586. View

15.

Chung V, Tattersall M, Cheung H . Interactions of a herbal combination that inhibits growth of prostate cancer cells. Cancer Chemother Pharmacol. 2004; 53(5):384-90. DOI: 10.1007/s00280-003-0746-1. View

16.

Li W, Zhang X, Xin Y, Xuan Y, Liu J, Li P . Oral subchronic toxicity evaluation of a novel antitumor agent 25-methoxydammarane-3, 12, 20-triol from Panax notoginseng in Sprague-Dawley rats. Regul Toxicol Pharmacol. 2016; 77:240-51. DOI: 10.1016/j.yrtph.2016.03.013. View

17.

Bi X, Zhao Y, Fang W, Yang W . Anticancer activity of Panax notoginseng extract 20(S)-25-OCH3-PPD: Targetting beta-catenin signalling. Clin Exp Pharmacol Physiol. 2009; 36(11):1074-8. DOI: 10.1111/j.1440-1681.2009.05203.x. View

18.

Baek K, Yi Y, Son Y, Yoo S, Sung N, Kim Y . and anti-inflammatory activities of Korean Red Ginseng-derived components. J Ginseng Res. 2016; 40(4):437-444. PMC: 5052440. DOI: 10.1016/j.jgr.2016.08.003. View

19.

Shin J, Lee J, Shin H, Park S, Yang J, Cho S . Anti-Cancer Effect of Ginsenoside F2 against Glioblastoma Multiforme in Xenograft Model in SD Rats. J Ginseng Res. 2013; 36(1):86-92. PMC: 3659572. DOI: 10.5142/jgr.2012.36.1.86. View

20.

Cui C, Kim J, Kim S, Im W . Characterization of a ginsenoside-transforming β-glucosidase from Paenibacillus mucilaginosus and its application for enhanced production of minor ginsenoside F₂. PLoS One. 2014; 9(1):e85727. PMC: 3903488. DOI: 10.1371/journal.pone.0085727. View